Document Detail

Malignancy: Subsequential Alterations of Telomeric DNA Length Correlate with Cytogenetic Response in Chronic Myeloid Leukemia Treated with Interferon alpha.
MedLine Citation:
PMID:  11399549     Owner:  NLM     Status:  Publisher    
Telomeres consist of simple tandem hexametric (TTAGGG) repeats and progressively shorten with cell replication. To determine a relationship between telomeric erosion and response to treatment, we measured telomere length following treatment in patients with chronic myeloid leukemia (CML) in the chronic phase. We used 70 samples of bone marrow mononuclear cells obtained from 26 patients with CML in the chronic phase subsequently. Telomere length was determined by a Southern hybridization of HinfI-digested DNA using a (TTAGGG)(4) probe, and the terminal restriction fragment (TRF) length was measured. Telomerase activity was also measured in 14 CML patients at the time of diagnosis using a telomeric repeat amplification protocol (TRAP) assay. Of the 26 patients with CML at the time of diagnosis, 14 had normal TRF lengths and the remaining 12 had shortened TRFs compared to those of age-matched normal individuals. In a group of CML patients treated with interferon alpha (IFNalpha), 80% of those who showed normal TRFs obtained cytogenetic responses. Approximately 50% of patients with shortened TRFs and treated with IFNalpha showed normalization of TRFs after IFNalpha treatment and all of them were cytogenetic responders. None of the CML patients with shortened TRFs before and after IFNalpha treatment achieved major cytogenetic response and they had high levels of telomerase activity. In the group of CML patients treated with hydroxyurea alone, although some patients showed normalization of TRF lengths after treatment, none of them showed major cytogenetic response. Telomere length before treatment may be related to CML disease severity. Cytogenetic response could be expected in CML patients with normal TRF lengths and treated with IFNalpha. Thus, measurement of telomere length after treatment might provide important information in managing CML patients.
SHIGEFUMI Hayashi; HIROSHI Iwama; NAOYUKI Yahata; KEIKO Ando; JUNKO H. Ohyashiki; KAZUMA Ohyashiki
Related Documents :
3472649 - Trisomy 9 in hematologic disorders: possible association with primary thrombocytosis.
19671939 - Cytologic phenotypes of b-cell acute lymphoblastic leukemia-a single center study.
3477869 - Old age: a sign of poor prognosis in patients with chronic myelogenous leukemia.
2719579 - Ophthalmic manifestations of leukemia.
2293879 - Results of chromosome studies and their relation to morphology, course, and prognosis i...
16914909 - Clonal karyotype evolution involving ring chromosome 1 with myelodysplastic syndrome su...
16027399 - Conversion from subcutaneous to intravenous erythropoietin in a hemodialysis population.
20379299 - Characteristics and predictors of recurrence of anterior and intermediate uveitis in a ...
17377019 - Costs of achieving high patient compliance after recall from screening mammography.
Publication Detail:
Journal Detail:
Title:  Hematology (Amsterdam, Netherlands)     Volume:  4     ISSN:  1607-8454     ISO Abbreviation:  Hematology     Publication Date:  1999  
Date Detail:
Created Date:  2001-Jun-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9708388     Medline TA:  Hematology     Country:  -    
Other Details:
Languages:  ENG     Pagination:  1-10     Citation Subset:  -    
First Department of Internal Medicine, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hermansky-Pudlak syndrome.
Next Document:  Malignancy: Human T-Cell Lymphotropic Virus Type I and Adult T-Cell Leukaemia/Lymphoma.